Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies

Treatment with rituximab, a monoclonal antibody against the B-lymphocyte surface protein CD20, leads to the depletion of B cells. Recently, rituximab was reported to effectively prevent relapses of glucocorticoid-dependent or frequently relapsing minimal change disease (MCD). MCD is thought to be T-...

Descripción completa

Detalles Bibliográficos
Autores principales: Madanchi, Nima, Bitzan, Martin, Takano, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Narrative Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433659/
https://www.ncbi.nlm.nih.gov/pubmed/28540057
http://dx.doi.org/10.1177/2054358117698667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433659/
https://www.ncbi.nlm.nih.gov/pubmed/28540057
http://dx.doi.org/10.1177/2054358117698667

Ejemplares similares